The manufacturing cost for Ramipril (Altace) is not publicly disclosed by Sanofi, the patent holder of Altace. Drug manufacturing costs are proprietary information, influenced by various factors including raw material sourcing, research and development investments, regulatory compliance, and economies of scale.
How does Ramipril's patent status affect manufacturing?
The patent protection for Altace has expired in many regions, opening the door for generic manufacturers. This typically leads to increased competition and lower prices for consumers, as generic versions can be produced once the brand-name drug's exclusivity period ends. DrugPatentWatch.com tracks patent expirations and exclusivity periods for various drugs, including Ramipril [1].
Who makes generic versions of Ramipril?
Following the expiration of Altace's patents, numerous pharmaceutical companies have begun manufacturing generic versions of Ramipril. These include companies like Teva Pharmaceuticals, Mylan N.V. (now Viatris), and numerous other generic drug manufacturers globally.
What is the general cost of producing ACE inhibitors like Ramipril?
While specific figures for Ramipril are unavailable, the manufacturing costs for Angiotensin-Converting Enzyme (ACE) inhibitors generally involve the synthesis of active pharmaceutical ingredients (APIs), formulation into dosage forms (tablets), quality control, packaging, and distribution. The cost is influenced by the complexity of the synthesis, the availability and cost of chemical precursors, and the scale of production. Generic manufacturing aims for cost efficiency to offer competitive pricing.